Jae‐Hoon Kim

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.8K citations

Brca1/2 Mutation, Medicine, Cancer Management +10

MicroRNA Expression Profiles in Serous Ovarian Carcinoma

Eun Ji Nam, Heejei Yoon, Sang Wun Kim et al. · Clinical Cancer Research · 2008 · 752 citations · Full text

Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment

Hanbyoul Cho, Hye Won Hur, Sang Wun Kim et al. · Cancer Immunology Immunotherapy · 2008 · 526 citations · Full text

Lymphoid Neoplasia, Pre-treatment Neutrophil, Epithelial Ovarian Cancer +7

Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer

Jae‐Hoon Kim · JAMA · 2002 · 504 citations · Full text

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

Andrés Poveda, Anne Floquet, Jonathan A. Ledermann et al. · The Lancet Oncology · 2021 · 391 citations · Full text